Ontology highlight
ABSTRACT:
SUBMITTER: Gadaleta-Caldarola G
PROVIDER: S-EPMC9600707 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature
Gadaleta-Caldarola Gennaro G Rizzo Alessandro A Dadduzio Vincenzo V Lombardi Lucia L Gadaleta-Caldarola Arianna A Infusino Stefania S Cusmai Antonio A Citrigno Claudia C Palmiotti Gennaro G
Current oncology (Toronto, Ont.) 20221019 10
Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemigatinib, whose approval has marked a new era in this hepatobiliary malignancy. However, a number of questions remain unanswered, including the development of secondary resistance and the role of combination therapies, including FGFR inhibitors. Herein ...[more]